Business · 25/09/2024Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for OMLONTI Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for OMLONTI, a human drug product, following submissions to the USPTO for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →